Pieris appoints chief scientific officer

Joins German firm from Merck & Co bringing therapeutic protein drug development expertise

Laurent Audoly has joined Pieris as chief scientific officer. Audoly, most recently Biologics Research Site Lead at Merck & Co, brings both pharma and biotech experience to the German biotechnology company, particularly expertise in therapeutic protein drug development.

‘Laurent’s pharmacology expertise and drug development skills are the precise ingredients we need to maximise the value of our growing therapeutic pipeline,’ saidd Stephen Yoder, chief executive of Pieris.

‘As the company builds and expands its internal and partnered Anticalin pipeline, Laurent's contribution will be significant.’

You may also like

Regulatory

Commercialised anticalin inhaled treatments

Pieris Pharmaceuticals and AstraZeneca collaborate to develop and commercialise treatments for respiratory diseases
Ingredients

Pieris announces first cancer immunotherapy collaboration

Agreement with Roche leverages proprietary Anticalin technology platform
Research & Development

Pieris Pharmaceuticals and the University of Melbourne receive grant

To advance Anticalin-based therapeutic for inhaled delivery to treat asthmatics
Ingredients

Zydus Cadila and Pieris to collaborate on anticalin development

Collaboration combines Pieris’s drug discovery and early development capabilities with Zydus’s expertise in biologics development, regulatory affairs and biologics manufacturing
Research & Development

Cirena and Epigenica launch technologies to accelerate genome editing and epigenomic research

Two life sciences companies have announced new technologies designed to address long-standing bottlenecks in genome editing and epigenomic analysis, offering faster timelines and improved reproducibility for researchers in academia and industry
Research & Development

PSI launches platform to speed up site ID, startup and enrolment in pivotal studies

SYNETIC is designed to speed up site identification, startup and patient enrollment in pivotal clinical trials
Ingredients

Piramal Pharma Solutions introduces tablet-in-capsule capabilities

Enhancing dosing flexibility and patient-centric drug delivery
Subscribe now